Join to View Full Profile
1305 York AveFl 12New York, NY 10021
Phone+1 646-962-6200
Fax+1 646-962-1607
Dr. Siegel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2002 - 2004
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2002- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
University of Massachusetts Medical SchoolClass of 1997
Certifications & Licensure
NY State Medical License 1999 - 2024
CT State Medical License 2010 - 2019
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- S1204, Viral Screening in Newly Diagnosed Cancer Patients Start of enrollment: 2013 Aug 29
- Join now to see all
Publications & Presentations
PubMed
- 81 citationsPembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu
Journal of Clinical Oncology. 2023-03-01 - 46 citationsPembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe
Clinical Cancer Research. 2022-06-13 - 56 citationsUpdated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.Masatoshi Kudo, Richard S Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
European Journal of Cancer. 2022-05-01
Press Mentions
'Brave, Compassionate and Dedicated': ER Doctor Who Treated Coronavirus Patients Dies by SuicideApril 29th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
